# PhotoPharmics **Type:** venture **Status:** Draft **Confidence:** Medium **Focus:** phototherapy, neurodegenerative disease, Parkinson's disease, medical devices, circadian biology **Stage:** Private; clinical-stage; Series B ($16M + $6M extension); Phase 3 trial underway **Location:** American Fork, UT **Updated:** 2026-06-19 **Needs-reviewed:** 2026-06-19 **Hero:** https://picsum.photos/seed/photopharmics-2026/1600/1100 **Pull:** *A home-based light device targeting the retinal-circadian axis — not symptoms alone — in Parkinson's disease.* **Relates:** cites [Official Website: PhotoPharmics](photopharmics-official-website.md) ## Summary PhotoPharmics is a Utah-based, clinical-stage medical device company developing non-invasive phototherapy for neurodegenerative disease. Founded around 2015 and headquartered in American Fork, the company is advancing Celeste® — a tablet-sized, home-use photo-neuromodulation device that delivers precisely calibrated light through the eye's non-visual photoreceptors. The scientific bet is that intrinsically photosensitive retinal ganglion cells (ipRGCs) modulate circadian and dopaminergic pathways disrupted in Parkinson's disease. Celeste has FDA Breakthrough Device designation, and the company is running a Phase 3 pivotal trial ("Light for PD") while building on prior Phase 2 data published in *Neurotherapeutics*. ## Impact Parkinson's is among the fastest-growing neurological disorders by prevalence. Standard care — levodopa, deep brain stimulation — largely addresses symptoms rather than underlying circadian and photoreceptor biology. If Celeste demonstrates durable, disease-modifying benefit at Phase 3 scale, it could become the first non-pharmacological, non-invasive disease-modifying treatment for Parkinson's: a device with no systemic drug side effects. The counterfactual is substantial. Without this work, patients remain on symptomatic regimens that lose efficacy over time and carry significant side effects. Even meaningful slowing of progression would matter at global scale — roughly one million new Parkinson's diagnoses occur annually worldwide. Founders bring 30+ years in phototherapy and previously developed circadian light solutions acquired by Philips Respironics, so the mechanism is not a first-time hypothesis for this team. ## What They Are Building Celeste® is an investigational, home-based photo-neuromodulation device. Spectral engineering targets ipRGC activation without the glare of conventional visual photoreceptor stimulation. The company's public positioning frames the work as exploring retinal-circadian signaling in neurological function, with Parkinson's as the initial clinical focus and additional neurodegenerative applications possible through future programs. Beyond the device itself, PhotoPharmics is executing a multi-phase clinical program — Phase 2 results peer-reviewed, Phase 3 enrollment progressing toward readout — while expanding board capacity for commercialization and partnerships. ## What They Need Now Likely needs include neuroscientists, biomedical engineers with photonics or optics backgrounds, clinical trial operations specialists, regulatory affairs experts, and commercial leaders who can navigate payer coverage for a novel therapeutic device. The team is relatively small and Utah County-based — a fit for contributors who want proximity to the science rather than a large pharma apparatus. Capital may also be a near-term need: total Series B funding ($16M plus a $6M oversubscribed extension) is modest for a Phase 3 therapeutic, which could reflect lean operations or an upcoming raise to complete enrollment and commercial readiness. ## Who Could Help Useful helpers include Parkinson's clinical investigators, medical-device regulatory consultants, photonics and vision-science researchers, payer and reimbursement strategists, Salt Lake City venture investors familiar with life-science devices (Kickstart Fund led the Series B), and patient-advocacy organizations that can support trial awareness and eventual adoption. ## Utah Context PhotoPharmics is a Wasatch Front clinical-device company with deep roots in Utah County phototherapy research. It sits in the state's health-and-longevity cluster alongside BioUtah-connected life-science ventures. Press and company materials reference Utah operations; the work is a local example of translating circadian and retinal biology into an FDA-track therapeutic device. ## Evidence - [Official Website: PhotoPharmics](photopharmics-official-website.md) ## Open Questions - Phase 3 primary-endpoint efficacy remains genuinely uncertain — Breakthrough Device designation reflects FDA interest in the mechanism, not a prediction of trial success. - The "Light for PD" trial enrolled 200+ participants toward a ~300-participant target; results were pending as of legacy intake and should be revisited at data readout. - Post-approval payer coverage for a novel light-therapy device is a real commercial hurdle with a complicated regulatory and market history for similar modalities. - ~10 years of operation at relatively modest funding could reflect deep scientific diligence or slow commercial progress — which interpretation fits is unclear without independent financial disclosure. - Company press references Salt Lake City in some releases while legacy intake lists American Fork HQ — exact facility footprint should be confirmed. - The placeholder hero should be replaced with a cleared product or clinical image when rights are confirmed.